Close Menu

NEW YORK (GenomeWeb) – HTG Molecular reported after the close of the market on Thursday a 25 percent rise in total revenues for its fourth quarter.

For the three months ended Dec. 31, 2016, the company reported total revenues of $1.5 million, compared to $1.2 million in Q4, 2015. While service revenues rose to $381,221 from $33,466 a year ago, product revenues shrank 8 percent year over year to $1.1 million from $1.2 million.

The company reduced its R&D costs 18 percent to $1.4 million from $1.7 million, while its SG&A costs remained stable at $4.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.